Siemens Healthineers Q1 2026 results to reveal growth and challenges ahead

Siemens Healthineers is set to release its first-quarter results for fiscal year 2026 on February 5. The announcement will coincide with the company's annual general meeting, where shareholders can question management on strategy and performance. Investors are particularly interested in how the four core divisions—Imaging, Diagnostics, Varian, and Advanced Therapies—will shape growth in the coming months.

The Imaging division is expected to lead growth in Q1 2026, with Bank of America forecasting results above market expectations. However, management has warned that 2026 will be a transitional year, with tariffs and currency fluctuations likely to cut earnings per share by around 0.30 euros.

The diagnostics business, especially its performance in China, will also come under close scrutiny. Market dynamics in the region could influence short-term demand, which remains sensitive to healthcare budgets and investment cycles. Meanwhile, the long-term outlook for medical technology stays positive due to demographic changes and healthcare advancements.

Investors will watch for signs of progress in the integration of Varian, the cancer care specialist acquired in 2021. While no specific details on synergies or Advanced Therapies performance have been disclosed, the quarterly figures will reveal how these factors are affecting operations. Shareholders attending the annual general meeting will have the opportunity to press executives for clarity on future plans and challenges.

The upcoming results will provide insight into how Siemens Healthineers is navigating short-term pressures while positioning itself for long-term growth. The company's ability to manage currency risks, tariffs, and divisional performance will be key factors in determining investor confidence moving forward.